RhumbLine Advisers
SPRO icon

RhumbLine Advisers’s Spero Therapeutics SPRO Stock Holding History

RhumbLine Advisers’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-458
Closed -$595 – 4321
2024
Q2 		$595 Hold
458
– – ﹤0.01% 4279
2024
Q1 		$787 Hold
458
– – ﹤0.01% 4165
2023
Q4 		$673 Hold
458
– – ﹤0.01% 4184
2023
Q3 		$554 Hold
458
– – ﹤0.01% 4227
2023
Q2 		$664 Buy
+458
New +$784 ﹤0.01% 4308
2022
Q2 		– Sell
-24,740
Closed -$215K – 3224
2022
Q1 		$215K Buy
24,740
+5,479
+28% +$56.1K ﹤0.01% 2739
2021
Q4 		$308K Sell
19,261
-329
-2% -$5.22K ﹤0.01% 2694
2021
Q3 		$361K Buy
19,590
+1,025
+6% +$16.4K ﹤0.01% 2692
2021
Q2 		$259K Buy
18,565
+126
+0.7% +$1.76K ﹤0.01% 2842
2021
Q1 		$271K Sell
18,439
-777
-4% -$13.7K ﹤0.01% 2737
2020
Q4 		$373K Buy
19,216
+4,568
+31% +$71.2K ﹤0.01% 2569
2020
Q3 		$163K Sell
14,648
-3,281
-18% -$38.8K ﹤0.01% 2747
2020
Q2 		$243K Buy
17,929
+1,512
+9% +$17K ﹤0.01% 2677
2020
Q1 		$133K Buy
16,417
+1,030
+7% +$9.08K ﹤0.01% 2711
2019
Q4 		$148K Buy
15,387
+345
+2% +$3.72K ﹤0.01% 2820
2019
Q3 		$159K Buy
15,042
+1,481
+11% +$15.6K ﹤0.01% 2801
2019
Q2 		$156K Buy
13,561
+2,668
+24% +$32.1K ﹤0.01% 2851
2019
Q1 		$140K Buy
10,893
+883
+9% +$9.37K ﹤0.01% 2814
2018
Q4 		$62K Buy
+10,010
New +$81.1K ﹤0.01% 2926

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

RhumbLine Advisers's SPRO Position: Q3 2024 in Review

RhumbLine Advisers sold out of Spero Therapeutics (SPRO) in Q3 2024, closing a stake of 458 shares — an estimated $595 sold.

RhumbLine Advisers first reported a position in SPRO in Q4 2018 and held it in 19 quarters. The position peaked at $373K in Q4 2020. 46 funds tracked by Wall St. Rank hold SPRO as of Q3 2024.

  • RhumbLine Advisers reported no remaining Spero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 458 Spero Therapeutics shares in Q3 2024, an estimated $595.
  • RhumbLine Advisers first reported a position in Spero Therapeutics in Q4 2018 and held it in 19 quarters.
  • RhumbLine Advisers's Spero Therapeutics position peaked at $373K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.